Two more lawsuits filed against makers of heartburn drug Reglan
Two more lawsuits have been filed in federal court in New Orleans against the manufacturers of an acid reflux medication that allegedly causes a debilitating involuntary movement disorder known as tardive dyskinesia. Ellen Austin filed a suit against Actavis, Actavis Elizabeth and Watson Pharmaceuticals. Leslie Keeper filed suit against Qualitest Pharmaceuticals. Both lawsuits claim the drug Reglan, also known as the generic metoclopramide, caused them to develop the movement disorder.
![[ Beasley Allen Law Firm Logo ]](http://www.reglan-lawyer.net/wp-content/themes/system-unity/images/logo.png)

An Atlanta woman is suing Pliva, Inc., makers of the prescription heartburn medication
When 57-year-old August Macaluso, a former nuclear-plant maintenance worker in Charlotte, N.C., began shaking violently, blinking incessantly and slurring his speech, he and his wife Sharon were both puzzled. Desperate for answers, Sharon Googled his symptoms and learned that the drug her husband had been taking for just three months was linked to the involuntary movement disorder
Wyeth, Inc. and Schwarz Pharma Inc. have been dismissed from a lawsuit filed in Texas involving the drug company’s
People with movement disorders that are inherited or caused by infection or other occurrences, such as Parkinson’s disease, have a bevy of resources available. But for those whose debilitating condition came as a result of medication have little support. The
The medication
Last March, the U.S. Supreme Court upheld a $6.7 million ruling stating that federal law cannot protect pharmaceutical companies from liability lawsuits that are filed in state court, meaning drug companies are responsible for damages created by products even when the FDA has approved drug labels that include warnings of side effects. That ruling is based on a lawsuit involving Wyeth Pharmaceutical drug Phenergan. As a result of the ruling, numerous lawsuits against pharmaceutical companies that had been lying dormant are finally beginning to move toward trial, according to